These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8886299

  • 1. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers.
    Koszycki D, Zacharko RM, Le Melledo JM, Young SN, Bradwejn J.
    Biol Psychiatry; 1996 Oct 01; 40(7):648-55. PubMed ID: 8886299
    [Abstract] [Full Text] [Related]

  • 2. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
    Abelson JL, Nesse RM.
    Biol Psychiatry; 1994 Jul 15; 36(2):73-83. PubMed ID: 7948449
    [Abstract] [Full Text] [Related]

  • 3. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
    McCann UD, Slate SO, Geraci M, Uhde TW.
    Anxiety; 1994 Jul 15; 1(6):258-67. PubMed ID: 9160584
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
    Katzman MA, Duffin J, Shlik J, Bradwejn J.
    Neuropsychopharmacology; 2002 Jun 15; 26(6):824-31. PubMed ID: 12007753
    [Abstract] [Full Text] [Related]

  • 8. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
    Schunck T, Mathis A, Erb G, Namer IJ, Hode Y, Demazières A, Luthringer R.
    J Psychopharmacol; 2011 Jan 15; 25(1):52-9. PubMed ID: 20498136
    [Abstract] [Full Text] [Related]

  • 9. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
    Bradwejn J, Koszycki D, Shriqui C.
    Arch Gen Psychiatry; 1991 Jul 15; 48(7):603-10. PubMed ID: 2069490
    [Abstract] [Full Text] [Related]

  • 10. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
    Demiralay C, Agorastos A, Yassouridis A, Jahn H, Wiedemann K, Kellner M.
    Psychoneuroendocrinology; 2017 Feb 15; 76():14-18. PubMed ID: 27871026
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers.
    Shlik J, Vasar V, Aluoja A, Kingisepp PH, Jagomägi K, Vasar E, Rägo L, Bradwejn J.
    Biol Psychiatry; 1997 Aug 01; 42(3):206-12. PubMed ID: 9232213
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep.
    Kronenberg G, Schredl M, Fiedler K, Heuser I.
    Depress Anxiety; 2001 Aug 01; 14(2):141-4. PubMed ID: 11668667
    [Abstract] [Full Text] [Related]

  • 16. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
    Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K.
    Depress Anxiety; 2006 Aug 01; 23(3):139-44. PubMed ID: 16470820
    [Abstract] [Full Text] [Related]

  • 17. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.
    Tõru I, Shlik J, Maron E, Vasar V, Nutt DJ.
    Psychopharmacology (Berl); 2006 May 01; 186(1):107-12. PubMed ID: 16541242
    [Abstract] [Full Text] [Related]

  • 18. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms.
    Le Mellédo JM, Bradwejn J, Koszycki D, Bichet DG, Bellavance F.
    Biol Psychiatry; 1998 Sep 01; 44(5):364-6. PubMed ID: 9755359
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
    Fossa AA, DePasquale MJ, Morrone J, Zorn SH, Bryce D, Lowe JA, McLean S.
    J Pharmacol Exp Ther; 1997 Apr 01; 281(1):180-7. PubMed ID: 9103496
    [Abstract] [Full Text] [Related]

  • 20. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
    Koszycki D, Torres S, Swain JE, Bradwejn J.
    Psychosom Med; 2005 Apr 01; 67(4):590-5. PubMed ID: 16046372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.